incretin hormone raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-03. Anything still debated is marked as such rather than presented as settled.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
The chloroplasts of plant and algal cells can orient themselves to best suit the available light. In low-light conditions, they will spread out in a sheet—maximizing the surface area to absorb light. Under intense light, they will seek shelter by aligning in vertical columns along the plant cell's cell wall or turning sideways so that light strikes them edge-on. This reduces exposure and protects them from photooxidative damage. This ability to distribute chloroplasts so that they can take shelter behind each other or spread out may be the reason why land plants evolved to have many small chloroplasts instead of a few big ones. Chloroplast movement is considered one of the most closely regulated stimulus-response systems that can be found in plants. Mitochondria have also been observed to follow chloroplasts as they move. In higher plants, chloroplast movement is run by phototropins, blue light photoreceptors also responsible for plant phototropism. In some algae, mosses, ferns, and flowering plants, chloroplast movement is influenced by red light in addition to blue light, though very long red wavelengths inhibit movement rather than speeding it up. Blue light generally causes chloroplasts to seek shelter, while red light draws them out to maximize light absorption. Studies of Vallisneria gigantea, an aquatic flowering plant, have shown that chloroplasts can get moving within five minutes of light exposure, though they don't initially show any net directionality.
Additionally, operating these two-stage systems under thermophilic conditions (55 °C) has been validated as a robust strategy for full-scale applications, allowing for higher organic loading rates and optimized energy recovery compared to single-stage configurations.
While the nanomaterials themselves often cannot be eliminated or substituted with conventional materials, it may be possible to choose properties of the nanoparticle such as size, shape, functionalization, surface charge, solubility, agglomeration, and aggregation state to improve their toxicological properties while retaining the desired functionality. Handling procedures can also be improved, for example, using a nanomaterial slurry or suspension in a liquid solvent instead of a dry powder will reduce dust exposure. Engineering controls are physical changes to the workplace that isolate workers from hazards, mainly ventilation systems such as fume hoods, gloveboxes, biosafety cabinets, and vented balance enclosures. Administrative controls are changes to workers' behavior to mitigate a hazard, including training on best practices for safe handling, storage, and disposal of nanomaterials, proper awareness of hazards through labeling and warning signage, and encouraging a general safety culture. Personal protective equipment must be worn on the worker's body and is the least desirable option for controlling hazards. Personal protective equipment normally used for typical chemicals are also appropriate for nanomaterials, including long pants, long-sleeve shirts, and closed-toed shoes, and the use of safety gloves, goggles, and impervious laboratory coats. In some circumstances respirators may be used. Exposure assessment is a set of methods used to monitor contaminant release and exposures to workers.
The Legislative Reorganization Act of 1970 renewed emphasis for the library on its legislative roles, requiring a greater focus on research for Congress and congressional committees, and renaming the Legislative Reference Service as the Congressional Research Service.
Sources: en.wikipedia.org
=== Medicine === Melamine derivatives of arsenical drugs are potentially important in the treatment of African trypanosomiasis. Melamine use as non-protein nitrogen (NPN) for cattle was described in a 1958 patent. In 1978, however, a study concluded that melamine "may not be an acceptable non-protein N source for ruminants" because its hydrolysis in cattle is slower and less complete than other nitrogen sources such as cottonseed meal and urea.
== Early career == After graduating from MIT, Swanson took a job at Citibank, where he managed a venture investment group. His performance pleased his supervisors, and he and a colleague were chosen to open a San Francisco office for Citicorp Venture Capital. However, the new Citicorp investments were not doing well. One particular failure, which Swanson later believed to have been a lucky break, was the bankruptcy of Antex, a science based company that Citicorp had invested in. He worked with Eugene Kleiner, another Citicorp executive, to attempt to get some money out of the company's bankruptcy. Eugene Kleiner was the cofounder of the venture capital partnership Kleiner & Perkins. Swanson left Citicorp and joined Kleiner & Perkins in 1974, under the recommendation of Eugene Kleiner himself. As an associate, Swanson spent a lot of time and effort attempting to convince the heads of the science company Cetus, one which Kleiner and Perkins had invested in, to pursue genetic recombination projects. His interest in the technology had been piqued in a lunch with famed scientist and Nobel laureate Donald Glaser. However, the company refused to take on such a risky endeavor, and Kleiner & Perkins parted ways with the company. This falling out was one of the main reasons for the group's decision to advise Swanson to look for another job. Kleiner & Perkins had decided that they would rather work alone, and by the end of 1975, Swanson's position there would be terminated.
== Medical uses == Brimonidine is indicated for the lowering of intraocular pressure in people with open-angle glaucoma or ocular hypertension. It is also used to reduce redness of the eye. The gel is indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. A 2017 Cochrane review found insufficient evidence to determine if brimonidine slows optic nerve damage.
Sources: en.wikipedia.org
===== MeSH D08.811.277.087 – amidohydrolases ===== MeSH D08.811.277.087.030 – N-acetylmuramoyl-L-alanine amidase MeSH D08.811.277.087.060 – allophanate hydrolase MeSH D08.811.277.087.100 – arylformamidase MeSH D08.811.277.087.116 – asparaginase MeSH D08.811.277.087.125 – aspartylglucosylaminase MeSH D08.811.277.087.180 – beta-lactamases MeSH D08.811.277.087.180.229 – cephalosporinase MeSH D08.811.277.087.180.697 – penicillinase MeSH D08.811.277.087.200 – biotinidase MeSH D08.811.277.087.280 – dihydroorotase MeSH D08.811.277.087.483 – glutaminase MeSH D08.811.277.087.520 – histone deacetylases MeSH D08.811.277.087.610 – nicotinamidase MeSH D08.811.277.087.690 – penicillin amidase MeSH D08.811.277.087.725 – peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase MeSH D08.811.277.087.760 – pyroglutamate hydrolase MeSH D08.811.277.087.831 – sirtuins MeSH D08.811.277.087.902 – urease
== Research facilities == RCB has established facilities in its interim campus at Gurgaon where it is functioning. Centre is expected to expand further when it moves to its permanent campus in Faridabad, within the NCR Biotech Science Cluster, later this year. RCB has established major specialized facilities that include: high resolution optical imaging (Atomic Force Microscopy, Confocal Microscopy, Fluorescence Microscopy), synthesis chemistry facilities, Protein sequencer, Protein purification systems, biophysical (Isothermal Titration Calorimetry, Differential Scanning Calorimetry, Circular Dichroism, SPR, NMR, FTIR, Dynamic Light Scattering), structural biology (Crystallization Robotics, X-ray Diffraction), proteomics (ABSciEx Triple TOF 5600), flow cytometry, plant, bacterial and animal cell/ tissue culture facilities, tissue sectioning and insect culture facilities. In addition, researchers at RCB have access to the Advanced Technology Platform Center (ATPC) of the Biotech Science Cluster Faridabad. The ATPC already houses an operational flow cytometry and proteomics facilities. Other high-end facilities planned to be operational in near future include complete optical imaging, electron microscopy and next-generation sequencing.
chemical processing, electricity, batteries and electronic components, construction and architecture, healthcare and pharmaceutics, biomedical research, ultra-pure applications, nuclear waste handling, petrochemical, oil and gas, food, beverage processing, water, wastewater management.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.